NEW YORK--(BUSINESS WIRE)--April 7, 2006--Callisto Pharmaceuticals, Inc. (AMEX:KAL - News; FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today updated information with respect to the Company's cash position following its latest financing activities. In addition, in compliance with American Stock Exchange Rule 610(b), it also announced that the Company's independent registered public accountants included an explanatory paragraph in their opinion on the Company's financial statements included in the recently filed Form 10-K for the year ended December 31, 2005, relating to the Company's ability to continue as a going concern.
